The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cynata Therapeutics (CYP) receives notice of allowance for a patent application covering its Cymerus mesenchymal stem cell (MSC) platform technology
  • A notice of allowance is sent to an applicant when the United States Patent and Trademark Office intends to issue a patent
  • The patent will be wholly owned by Cynata and describes a method for ensuring quality and purity of Cynata’s finished therapeutic MSC products
  • Cynata says it anticipates the granting of the patent to occur in February, with an expiration date of 15 November, 2037
  • Cynata Therapeutics last traded at 30 cents at 1:10 pm AEDT

Cynata Therapeutics (CYP) has received notice of allowance for a patent application covering its Cymerus mesenchymal stem cell (MSC) platform technology.

The company received the notice from the United States Patent and Trademark Office (USPTO) for the patent entitled “Pluripotent Stem Cell Assay”.

The patent will be wholly owned by Cynata and describes a method for ensuring quality and purity of Cynata’s finished therapeutic MSC products.

A notice of allowance is sent to an applicant when the USPTO intends to issue a patent.

The patent adds to the existing broad and comprehensive IP protection of the Cymerus manufacturing platform and its unique ability to yield highly consistent MSCs at scale, from a single donation. This will then be used to create therapeutic stem cell products.

Cynata Chief Operating Officer Dr Kilian Kelly said the company is delighted its product development activities have resulted in another patent.

“This important achievement adds to our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2037 and beyond,” Dr Kelly said.

“The novel method described in the patent specification and patent claims enhances our competitive position around the Cymerus platform which enables the production of consistent, high-quality mesenchymal stem cells at scale.

“These important characteristics afford a major competitive advantage in the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide.”

Cynata said it anticipates the granting of the patent to occur in February, with an expiration date of 15 November, 2037.

Cynata Therapeutics last traded at 30 cents at 1:10 pm AEDT.  

CYP by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Market closes the week on a high | 12 July 2024

The ASX200 closed up 0.9% to 7959 points. All sectors finished the day in the green…
ASX chart prices

Week 27 Wrap: ASX hits all time high; CBA shares’ two realities; US inflation hits 3% ahead of China plenum

The ASX200 ended the week at a fresh all time high. Can we hit 8,000pts by…
The Market Online Video

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Infini Resources (ASX:I88) has unveiled what it believes could be the highest ever soil sample uranium concentrations found in Newfoundland, Canada, at its
The Market Online Video

ASX Market Update: ASX hits new record on lower than expected US inflation | 12 July 2024

The ASX200 has claimed a new record, reaching above 7,950 points on the back of positive futures.